United States Veterinary Anti-Infectives Market

United States Veterinary Anti-Infectives Market Insights Forecasts to 2035  

• The United States Veterinary Anti-Infectives Market Size Was Estimated at USD 2.92 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.94% from 2025 to 2035
• The United States Veterinary Anti-Infectives Market Size is Expected to Reach USD 5.51 Billion by 2035

According to a research report published by Dicision Advisors & Consulting, The United States Veterinary Anti-Infectives Market?Size is anticipated to reach USD 5.51 Billion by 2035, growing at a CAGR of 5.94% from 2025 to 2035. The United States veterinary anti-infectives market growth is mainly driven by the growing concern about antibiotic resistance and the need for alternative treatments are driving pharmaceutical companies to focus on innovation and the development of new drugs.

Market Overview

Veterinary anti-infectious drug agents are used to prevent, control, and treat infections caused by bacteria, viruses, fungi, and parasites in animals. These drugs play an important role in maintaining animal health, improving livestock productivity, and ensuring food security by reducing the spread of infectious diseases. They include categories such as antibiotics, antivirals, antifungals, and antiparasitics, each targeting specific pathogens. In veterinary practice, anti-infectives are essential for both companion animals, such as dogs, cats, horses, and food-producing animals, which include cattle, poultry, swine, and aquaculture species. Their use not only safeguards animal welfare but also indirectly protects human health by preventing zoonotic diseases—illnesses that can be transmitted from animals to humans. Moreover, by controlling infections in livestock, they contribute to higher yields of meat, milk, and eggs, thus supporting the agricultural economy and food supply chain. The administration of veterinary anti-infectives may be oral, injectable, topical, or through medicated feed and water, depending on the infection type and animal species. Veterinary professionals are increasingly focusing on prudent prescribing, preventive healthcare, and alternatives like vaccines and probiotics to minimize reliance on anti-infectives.

Report Coverage

This research report categorizes the United States veterinary anti-infective market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States veterinary anti-infectives market. Recent market developments and competitive strategies, such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United States veterinary anti-infectives market.  

Driving Factor 

The veterinary anti-infectives market is driven by increasing animal infectious diseases, the adoption of pets, and the expansion of livestock production. Increasing awareness about zoonotic hazards, regulatory support for antimicrobial use, and promoting AI integration in diagnostics. Investment in R&D and accurate therapy increases efficacy, while global trade and food security concerns increase the need for advanced anti-infectious solutions.

Restraining Factor

The veterinary anti-infectives market is restrained by antibiotic resistance, stringent regulatory structures, and increasing anxiety over limited awareness in developing areas. High R&D costs, slow approval procedures, and increasing demand for alternative remedies also obstruct market growth and adopt anti-veterinary-infectious products.

Market Segmentation  

The United States veterinary anti-infectives market share is classified into animal, product, and route of administration.

• The livestock animals segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The United States veterinary anti-infectives market is segmented by animal into livestock animals and companion animals. Among these, the livestock animals segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to the burden of high disease among livestock such as cattle, boar, hen, and sheep, and anti-infectious diseases require frequent preventive and medical use. Animal protein, especially the increasing demand for beef, pork, and poultry, confirms the need for strong disease management.

• The antimicrobials segment dominated the market in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period

The United States veterinary anti-infectives market is segmented by product into antimicrobials and antifungals. Among these, the antimicrobials segment dominated the market in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. This is due to the high burden of bacterial infections in livestock and companion animals. Commonly used classes like tetracyclines and penicillins remain essential for treating respiratory and gastrointestinal diseases.

• The oral segment dominated the market in 2024 and is expected to grow at a significant CAGR during the forecast period.  

The United States veterinary anti-infectives market is segmented by route of administration into oral, injectable, and topical. Among these, the oral segment dominated the market in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to the ease of administration in fellow animals and food-producing livestock. To reduce medicated feed additives, compliance and treatment costs for animals without veterinary supervision. 

Competitive Analysis

The report offers the appropriate analysis of the key organizations/companies involved within the United States veterinary anti-infectives market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies 

• Zoetis
• Boehringer Ingelheim
• Merck & Co. Inc.
• Dechra Pharmaceuticals Plc.
• Elanco Animal Health
• Ceva Sante Animale
• Virbac
• Biogénesis Bagó
• Other

Key Target Audience

• Market Players 
• Investors 
• End-users 
• Government Authorities? 
• Consulting and Research Firm 
• Venture capitalists 
• Value-Added Resellers (VARs) 

Market Segment 

This study forecasts revenue at the United States, regional, and country levels from 2020 to 2035. Dicision Advisors has segmented the United States veterinary anti-infectives market based on the below-mentioned segments: 

United States Veterinary Anti-Infectives Market, By Animal

• Livestock Animal
• Companion Animal

United States Veterinary Anti-Infectives Market, By Product

• Antimicrobials
• Antifungals

United States Veterinary Anti-Infectives Market, By Route of Administration

• Oral
• Injectable
• Topical

FAQ’s

Q: What are veterinary anti-infectives?

A: Veterinary anti-infectives are drugs used to prevent, control, and treat infections in animals caused by bacteria, viruses, fungi, or parasites. They include antibiotics, antivirals, antifungals, and antiparasitics.

Q: What was the market size of the U.S. veterinary anti-infectives market in 2024?

The market size was estimated at USD 2.92 billion in 2024.

Q: What is the expected market growth for U.S. veterinary anti-infectives?

A: The market is expected to grow at a CAGR of 5.94% from 2025 to 2035, reaching USD 5.51 billion by 2035.

Q: What are the key drivers of U.S. veterinary anti-infectives market growth?

A: Drivers include rising animal infectious diseases, increasing pet adoption, livestock production expansion, awareness of zoonotic hazards, and investments in R&D and advanced therapies.

Q: What factors restrain market growth?

A: Market restraints include antibiotic resistance, strict regulations, high R&D costs, slow approval processes, and growing interest in alternative therapies.

Q: Which animal segment dominates the U.S. veterinary anti-infectives market?

A: Livestock animals (cattle, poultry, swine, etc.) held the largest market share in 2024 due to higher disease prevalence and frequent preventive treatment needs.

Q: Which product segment leads the U.S. veterinary anti-infectives market?

A: Antimicrobials dominate the market because bacterial infections are common in both livestock and companion animals.

Q: Which route of administration is most commonly used?

A: Oral administration dominates due to ease of use, lower treatment costs, and compliance, especially in livestock and companion animals.

Q: What are the main routes of administration for veterinary anti-infectives?

A: The main routes include oral, injectable, and topical.

Q: Who are the key players in the U.S. veterinary anti-infectives market?

A: Key companies include Zoetis, Boehringer Ingelheim, Merck & Co., Dechra Pharmaceuticals, Elanco, Ceva Sante Animale, Virbac, Biogénesis Bagó, and others.

Q: What is the report’s base year and historical data range?

A: The base year is 2024, with historical data analyzed from 2020–2023.